Updated on 6 May 2016
Rock Creek Pharmaceuticals Inc, a clinical-stage drug development company focused on the application of its lead compound to treat acute and chronic inflammatory conditions, has announced recent additions to the company's intellectual property (IP) portfolio.
The company has recently received a Decision to Grant a Patent from the Japanese Patent Office (Patent Application No: 2014-528385) for a pharmaceutical composition or dietary supplement containing anatabine or a derivative or isomer thereof. This decision marks the first approved patent for the company in Japan, which is the second largest drug market in the world, worth close to $80B. Numerous Japanese companies in-license drugs and compounds from overseas for development in Japan.
Additionally the company received from the European Patent Office a Notification of Intent to Grant a European patent for the administration of Anatabine to treat autism spectrum and seizure disorders. The company is now pleased to announce that patent ‘EP2701704 - Methods of Administering Anatabine to Treat Autism Spectrum Disorders and Seizure Disorders' was granted and published on April 13, 2016.
Finally, The US Patent and Trademark Office issued a Notice of Allowance on March 14, 2016 to the company for Application No. 14/167,285 entitled, ‘Methods of Providing Anti-inflammation Support'. This will be the first US issued patent regarding "use" of anatabine or anatabine citrate for treating inflammation, providing further support to the Company's focus on developing anti-inflammatory therapeutics. The Company expects the patent to be issued within the next several months.
The company's IP portfolio currently includes a composition of matter patent for anatabine citrate, a patent for large scale anatabine synthesis, and numerous US and foreign patents pending for ‘use' of anatabine and salts thereof, and its isomers and derivatives for inflammatory conditions. Those conditions include, but are not limited to, such diseases as psoriasis, thyroiditis, arthritis, Alzheimer's disease, and multiple sclerosis, as well as a recently published ‘patent pending' application for use of anatabine in various conditions of inflammatory lung disease.
Michael Mullan, Chairman and Chief Executive Officer of Rock Creek Pharmaceuticals, commented, "Comprehensive intellectual property protection is critical for the realization of the value of our pharmaceutical products under development. We are therefore pleased to repo